Study start-up pulse report
Survey finds that change is required in study start-up to improve trial performance and speed up the time it takes treatments to enter the market as the industry assesses its post-Covid-19 readiness
Add bookmark
New results from one of the industry's largest global clinical operations surveys has revealed a critical need for change in study start-up.
According to the findings of the Veeva 2020 Study start-up pulse report, modernizing study start-up systems and processes are among the greatest areas of opportunity to improve trial performance and bring treatments to market faster.
The report also looks at how to streamline information sharing and the core challenges associated with collaborative clinical trial processes.
Share best practice, ideas, and solutions to our global community of more than 125,000 senior pharmaceutical and biotech professionals. View our latest Media Kit to learn more about our audience and review our content calendar. Download NowInterested in presenting your own Case Study?
Download the report to discover:
- The drivers, barriers and benefits of modernizing clinical systems and processes to accelerate trials.
- What the industry-wide view of study start-up technology adoption is.
- Why modernizing study start-up systems and processes are among the greatest areas of opportunity to improve trial performance.
